Bausch + Lomb Corporation (BLCO)

Market Cap	7.16B +35.3%
Revenue (ttm)	5.42B +8.9%
Net Income	-111.00M
EPS	-0.31
Shares Out	357.50M
PE Ratio	n/a
Forward PE	17.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	598,008
Open	19.86
Previous Close	20.01
Day's Range	19.77 - 20.07
52-Week Range	14.44 - 21.36
Beta	0.56
Analysts	Buy
Price Target	21.71 (+8.39%)
Earnings Date	Oct 28, 2026

About BLCO

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 6, 2022
• Employees: 13,000
• Stock Exchange: NYSE
• Ticker Symbol: BLCO
• Website: https://www.bausch.com

Financial Performance

In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.

Analyst Summary

According to 15 analysts, the average rating for BLCO stock is "Buy." The 12-month stock price target is $21.71, which is an increase of 8.39% from the latest price.

Price Target

$21.71

(8.39% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 3, 2026

Data Sources Report a data error